February 2020 FDA Recall Memantine Hydrochloride by Lupin Pharmaceuticals Inc.
D-0855-2020 - Failed Dissolution Specifications

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on February 12, 2020 for the product Memantine Hydrochloride. The FDA reported the reason for recall as failed dissolution specifications. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0855-2020

Reason for Recall
Failed Dissolution Specifications: Low out of specification results observed in dissolution test at six-month long-term stability study.
Initiated
02-12-2020
Reported
02-19-2020
Quantity
6,294 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Nationwide within the United States.
Memantine Hydrochloride Extended Release Capsules, 21 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States. Manufactured by: Lupin Limited Pithampur (M.P.)-454 775, INDIA, NDC 68180-248-06

Batch or Lot Expiration Information

Lot# : H900330, exp. date 11/2020.